Louisiana Department of Health Confidential Report of Sexually Transmitted Diseases (STD)

PROVIDER INFORMATION							
	of Provi			Phone: ()			- Fax Number: () -
	ty Name:					Email:	
Address: City:							State: Zip
Name of Person Reporting: Position: PARTIENTED IN PROPERTY AND PROPERTY OF THE PROPERTY OF T							
PATIENT INFORMATION Patient Medical Rec. #:							
First N		11 Nec. #.		Middle Initial:	111	Last Name:	☐ Private ☐ Medicaid ☐ Unknown ☐ None
						Last Name.	Ctata: 7:m
Address: City: State: Zip Patient Hm Ph: () - Patient Wk Ph: () - Patient Cell Ph: () -							
		D/YYYY) /	/	SSN:			Emergency Contact:
	Birth:	□ Male	Gender:	☐Male ☐ Female			Pregnant:
_ interest _			☐ Transgender Male-to-Female			☐ Yes, Expected Delivery Date: / /	
			☐ Transgender Female-to Male			□ No □ Unknown	
Race:		☐ White ☐ Black ☐		cific Islander ☐ American Indian/Ala			askan Native Other/Unknown
Ethnicity:							
Gender of Partner(s): Male Female Transgender Male-to-Female Transgender Female-to-Male Unknown							
Uringenital (Urine, cervical, etc.) Test(s)Conducted: Recommended Treatment:							
		genitai (Orine, cervicai, e [/] Pharyngeal	tc.)	☐ Culture			☐ Azithromycin 1g orally in a single dose
				□ NAAT			OR Doxycycline 100 orally 2x/day for 7 days
CHLAMYDIA	Rectal			□ Nucleic Acid Probe			Alternative:
	Ophthalmia neonatorum			☐ Point of Care Test			☐ Erythromycin base 500 mg orally 4x/day for 7days
	☐ Proctitis			Other (specify):			OR Erythoromycin ethylsuccinate 800 mg orally 4x/day for 7days
	☐ Pelvic Inflammatory Disease (PID)						OR Levofloxacin 500 mg orally 1x/day for 7 days OR Ofloxacin 300mg orally 2x/day for 7 days
	☐ Pneumonia			Date Treatment Administered:			If Pregnant:
	Other (specify):			/			☐ Azithromycin 1 g orally in a single dose
	,			Date of prescription given:			\square Amoxicillin 500 mg orally 3x/day for 7 days
	Date of Specimen Collection:						OR Erythromycin base 500mg orally 4x/day for 7 days OR Erythromycin base 250 mg orally 4x/day for 14 days
	/						OR Erythromycin ethylsuccinate 800 mg orally 4x/day for 7 days
							OR Erythromycin ethylsuccinate 800 mg orally 4x/day for 14 days
GONORRHEA	Name of Testing Laboratory:						
	☐ Urogenital (Urine, cervical, etc.)			Test(s)Conducted:			Recommended Treatment:
	☐ Oral/Pharyngeal			Culture			□ Dual therapy with Ceftriaxone 250 mg IM in a single dose PLUS Azithromycin 1 g orally in a single dose or Doxycycline 100
	☐ Rectal			□ NAAT			mg orally twice a day for 7 days
	☐ Disseminated Gonococcal Infection (DGI)			□ Nucleic Acid Probe			Alternatives (*Note - Only if Ceftriaxone is not available)
	Ophthalmia neonatorum			☐ Point of Care Test			☐ Dual therapy with Cefixime 400 mg orally PLUS Azithromycin 1g
	Resistant Strain		☐ Other (specify): Date Treatment Administered:			Orally or Doxycycline 100 mg orally twice a day for 7 days	
	☐ Proctitis			/ /			If cephalosporin allergic:
	Pelvic Inflammatory Disease (PID)			Date of prescription given:			☐ Gemifloxacin 320 mg orally PLUS Azithromycin 2 g orally
C	☐ Other (specify): Date of Specimen Collection:			/			OR Gentamicin 240 mg IM PLUS Azithromycin 2 g orally
	Date of Specimen Collection:						
	Name of Testing Laboratory:						
	NOTE: Call to report [(504) 568-7474],			Test(s) Conducted & Results:			Recommended Treatment:
	then follow-up with form			RPR Titer			☐ 2.4 million units Benzathine Penicillin G (BIC) IM X 1 dose
	Primary (Genital or oral ulcer)		□ VDRL Titer			Date Administered:/	
SYPHILIS	☐ Secondary (Rashes)		☐ MHATP			☐ 2.4 million units Benzathine Penicillin G (BIC) IM X 3 doses	
	☐ Early non-primary non-secondary			□ FTA			Date 1 st Dose Administered:/
	☐ Unknown duration or Late syphilis			☐ IgG (EIA)			
		ary –Cardiovascular	☐ TP-PA			☐ Doxycycline 100 mg orally twice a day for 14 days	
	☐ Tertiary- Neurosyphilis			☐ Other			☐ Doxycycline 100 mg orally twice a day for 28 days
	☐ Congenital ☐ Other						☐ Other:
	Date of Specimen Collection:						Data managinting sincer.
							Date prescription given:/
	Name of Testing Laboratory:						
OTHER	☐ Herpes Simplex Virus (Neonates)			Test(s) Conducted & Results:			Treatment:
	Other (specify):						
LH	Date of Specimen Collection:						
0	No. of Total and Associated						
	Name of Testing Laboratory:						

LOUISIANA DEPARTMENT OF HEALTH CONFIDENTIAL REPORT OF SEXUALLY TRANSMITTED DISEASES (STD)

Form: STD 43 Revised April 2, 2018 (updates reflect new 2018 CDC syphilis case definitions)

DESCRIPTION & PURPOSE

The STD 43 is a single page form to report newly diagnosed, re-infected, and treated STDs with the exception of HIV/AIDS.

Directions for reporting HIV/AIDS cases contact: STD/HIV Program, 1450 Poydras Street Suite 2136, New Orleans, LA 70112, (504)568-7474. For information about HIV/AIDS Surveillance: http://ldh.la.gov/assets/oph/Center-PHCH/Center-PH/tuber/LouisianaAdministrativeCodeTitle51PublicHealthSanitaryCodeJan2010.pdf

INSTRUCTIONS FOR COMPLETING STD 43: CONFIDENTIAL REPORT OF SEXUALLY TRANSMITTED DISEASES Use one (1) form per person to report all applicable STDs. Print legibly.

Provider Information: Write the Name, Addresses, Phone number and Name of Person Reporting in the box or place a typed label with the same information over the box. If provider and facility are different, provide information for both. Services provided via the internet must list a valid medical provider and facility name.

Patient Information: Write the medical record #, First/Middle Initial/Last Name, Type of Insurance used for visit, Address, City/State/Zip Code, Phone number(s), Date of Birth (DOB), Social Security Number (SSN), in the spaces provided. Check the appropriate box (es) for Sex at Birth, Gender, Pregnancy status, Marital status, Race, Ethnicity, and Gender of Partner(s).

Disease: Check appropriate box (es) in this section depending on the diagnosis. In addition to completing the form, call the STD/HIV Program at (504)568-7474 to report all cases of primary & secondary syphilis.

For each disease reported complete each box in the appropriate column including:

- 1. Check the box (es) for the disease(s) being reported
- 2. Write the date laboratory specimens were collected
- 3. Write the name of the laboratory where tests were conducted
- 4. Check the box (es) for type of test(s) conducted that were positive. Syphilis test(s) conducted must be reported with results to identify new cases:
 - If RPR/VDRL is positive and confirmatory test (e.g., TPPA or IgG-EIA) is negative, report NEGATIVE confirmatory test result also (to validate biological false positives).
 - Enter titer result for the RPR and/or VDRL test (e.g., RPR 1:16, VDRL 1:128).
 - Report non-reactive/negative RPR/VDRL result if confirmatory test is positive (i.e. TPPA, IgG-EIA, FTA, etc.)
- 5. Write / check box (es) of medication given; write date treatment was administered and prescription was provided

Important Note:

Form STD 43 should be mailed to the STD/HIV Program as soon as the diagnosis is made. The form may be filled before treatment is completed. Patients should not be reported as cases unless the diagnosis is confirmed by appropriate tests. All contacts of STDs should be tested for the disease(s) to which they were exposed. If contacts are treated in the absence of positive laboratory tests, then they are considered epidemiologically treated. Epidemiologic treatment is applicable only to persons exposed to known STD cases. Therefore, the term does not apply to persons who are treated for symptoms only and are not, therefore, definitively diagnosed. Reporting of epidemiologic treatment should be withheld and reported only with positive laboratory tests.

MAIL or FAX FORM TO:

LOUISIANA DEPARTMENT OF HEALTH- STD/HIV Program

1450 Poydras Street Suite 2136 Or PO BOX 60630

New Orleans, LA 70112 NEW ORLEANS LA 70160

FAX to: (504)568-8384

For questions contact the STD/HIV Program at: 504-568-7474 or visit our web site at: http://www.LAHHUB.org.